Pulse Biosciences Announces New Data That Reinforce Potential Immuno-Oncology Benefits of Nano-Pulse Stimulation Technology

Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company
developing a proprietary therapeutic treatment platform based on
Nano-Pulse Stimulation (NPS), today announced the results of three
preclinical studies that further validate the NPS technology and its
potential role in novel immunotherapeutic approaches. The new data,
which will be presented November 11-12^th at the Society for
Immunotherapy of Cancer (SITC) Annual Scientific Meeting, demonstrate
that NPS triggered immunogenic cell death (ICD) in three separate cancer
cell lines and stimulated other beneficial anti-tumor immune responses
in two in vivo studies.
NPS is a non-thermal drug-free tissue treatment technology that involves
the local application of a series of ultrashort electrical pulses, each
lasting only hundreds of nanoseconds, directly to tissue through
electrodes. In preclinical models, NPS has shown the potential to
stimulate a signaling cascade within tumor cells that leads to ICD, or
immunogenic apoptosis (programmed cell death). This process not only
induces cell death in a natural way but also engages the immune system
to clear the treated cells and enroll cytotoxic T cells to recognize and
eliminate cells of the same tumor type.
“These new data add to the growing body of scientific evidence
supporting the use of NPS in the treatment of multiple tumor types,”
said Darrin Uecker, President and Chief Executive Officer of Pulse
Biosciences. “We believe the immune response observed in these recent
studies further indicate that NPS may have the ability to prime the
immune system and may be effective, and potentially even synergistic,
when used in combination with other immuno-therapeutics, with the
distinct advantage of not adding any drug related toxicity.”
The three studies presented at SITC showed that NPS treatment resulted
in potentially beneficial immune cell changes in both the primary tumor
and untreated secondary tumor microenvironment. Specific findings are as
follows:

• In one study presented, “Nanosecond pulsed electric field treatment of
  tumor cell lines triggers immunogenic cell death (ICD),” NPS induced
  three markers of ICD in three tumor cell lines, which the authors
  concluded could explain why in vivo NPS treatment has shown a
  vaccine-like effect that inhibits secondary tumor growth after
  subsequent challenges with tumor cells.
• In a second presented study, “Nanosecond pulsed electric field
  treatment of murine melanomas initiates an immune response and
  inhibits metastasis,” mice were given a single melanoma tumor which
  was later either removed surgically or by NPS treatment. When
  subsequently challenged with intravenously injected melanoma cells,
  the NPS-treated mice exhibited fewer metastases than did the mice that
  had surgical removal, suggesting that the immune system had removed
  some of the melanoma cells from circulation in the NPS treated mice.
  This observation extends NPS’s vaccination effect beyond secondary
  tumor challenge to circulating cancer cells.
• In the third study presented, “Adaptive immune response to Nano-Pulse
  Stimulation,” NPS treatment of murine fibrosarcoma tumors
  significantly increased the infiltration of immune system cells into
  the treated primary tumor and 3 weeks later challenge tumors were
  completely rejected due to the production and increase in
  functionality of T cells.

About Pulse Biosciences
Pulse Biosciences is a medical technology company developing a
therapeutic tissue treatment platform based on Nano-Pulse Stimulation, a
proprietary bioelectronics cell signaling technology. Published
pre-clinical studies have shown that a single, brief exposure of
Nano-Pulse Stimulation to target tissue stimulates a cascade of events
within cells and in the surrounding microenvironment that results in
apoptosis (programmed cell death) and the priming of a durable adaptive
immune response. Pulse Biosciences is pursuing a variety of applications
for its technology that exploits the technology’s unique biologic effect
in immuno-oncology, dermatology, aesthetics, and veterinary medicine.
Clinical studies are being planned using the first commercial system
designed to support a broad array of electrodes for use in superficial,
minimally-invasive and open surgical procedures. More information is
available at www.pulsebiosciences.com.
Forward Looking Statements
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
regarding or implying planned clinical trials and the anticipated
benefits, and other similar statements about future events. You should
not place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, changes in circumstances
and other factors that are, in some cases, beyond our control and could
cause actual results to differ materially from the information expressed
or implied by forward-looking statements made in this press release.
Factors that could materially affect actual results can be found in our
most recent filings with the Securities and Exchange Commission,
including our most recent reports on Forms S-1, as amended, and 10-Q,
and include those listed under the caption “Risk Factors.” These
forward-looking statements speak only as of the date hereof. Pulse
Biosciences undertakes no obligation to revise or update information in
this press release to reflect events or circumstances in the future,
even if new information becomes available.